Skip to content
Search

Latest Stories

PB Conference: 'Community pharmacy service during pandemic is great example of what integration should look like'

By ensuring delivery of key healthcare services and participating in the country’s largest vaccination drive during the tough times of the Covid-19 pandemic, community pharmacy has demonstrated integration in the sector, said Dr Nikki Kanani, medical director of primary care for NHS England.

“Not only have you (community pharmacy) delivered on this program, you've made sure that our most diverse communities have had access to the vaccine, at a time when demands of pharmacy and the health system are incredibly significant. That's exactly what integration means... in the context of pharmacy,” she said in her keynote address in the first session of the sixth annual Pharmacy Business Conference held online on Tuesday, September 21.


“We now have delivered vaccinations to over 89.2 per cent of adults in England, and two doses to 81 per cent of our adult population. So that is over 77 and a half million vaccinations.”

She added that incredible work done by community pharmacy and their teams helped in avoiding 143,600, Covid-19 hospitalisations, 24 million infections, and over 110,000 deaths.

Since 2018, NHS has been working on integration in pharmacy through the integrated care systems (ICSs). The system offers partnerships between the organisations that address health and care needs across an area, to coordinate services and to improve health and reduce inequalities between different groups.

Kanani said, “We now have 42 systems in that description, which are our health and care organisations coming together to join forces to really address our biggest health challenges.”

She noted that the future aim of NHS is to work in integration with communities and systems.

Talking about the key roles of ICS, Kanani said focus on community and addressing health inequalities is the most important factor and should be the foundation of ICS work.

Secondly, she highlighted the need for collaboration, which means to move away from competition and in favour of a collaborative, effective, proactive care that reflects the community.

Citing the example of GPs and community pharmacist, Kanani noted the third key role of ICS is to enable collaboration between providers on a bigger footprint, and "all the way through the emerging and growing integrated care system".

The main purpose of ICS is to improve healthcare, ensure equal outcomes through population health, enhance productivity and value for money by coming together and helping the NHS to support society and economic development, she said.

In November last year, NHS had published a policy paper entitled 'Integrating care: Next steps to building strong and effective integrated care systems across England', which focused on population health and addressed the wider health inequalities.

She added that during November 2020 and January 2021, “we heard from local leaders from all sorts of backgrounds (which) was a real statement of support, support for that vision.”

Also, more collaboration between councils, wider NHS partners is required. All these efforts are even more important as the country comes out of the pandemic.

In 2022, ICSs are expected to put in place system to enable a collective model of responsibility and decision-making between system partners.

Kanani said: “I have to believe that the future is bright because we have learned so much, we've been through so much together, we have to take the learnings of the last 18 months.

“Coming together around the community to address health inequalities and unequal outcomes has to be the best way not only getting great outcomes for our public, but also to look after each other in the best way possible.”

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less